Search

Your search keyword '"Zubiaga, Ana"' showing total 210 results

Search Constraints

Start Over You searched for: Author "Zubiaga, Ana" Remove constraint Author: "Zubiaga, Ana"
210 results on '"Zubiaga, Ana"'

Search Results

2. FRI-472-YI Mitochondrial metabolism is disrupted by ciprofloxacin preventing cholangiocarcinoma cell proliferation

3. THU-210 Dysfunctional activation of the DNA damage response is associated with MASLD progression through an E2F2-dependent mechanism

4. FRI-343-YI APAP induced liver damage is prevented by activation of PPARgamma and PPAR-alpha

5. TOP-229-YI The E2F2 target glycerophosphodiester phosphodiesterase domain containing 3 is involved in MASLD progression to HCC and related dyslipidemias

8. The E2F2-miR34a-5p axis is involved in the biliary metabolism dysregulation in NASH

9. Targeting the E2F/MCM axis in cholangiocarcinoma halts disease progression in experimental models by rewiring lipid metabolism

10. E2F2 deficiency protects from acetaminophen-induced hepatotoxicity while E2F1 is required to prevent the devastating effects

11. E2F2-promoted DNA damage in NASH worsens the metabolic scenario

12. Data from E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment

13. Supplementary Information from E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment

14. Supplementary Table 1 from E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment

15. Supplementary Data from E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment

16. Supplementary Table 2 from E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment

17. Supplementary Figures from E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment

18. Supplementary Table 3 from E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment

21. miR34a-5p is a target of E2F2 transcription factor in MAFLD-related HCC

22. The DNA damage response is involved in the metabolic dysregulation of MAFLD patients via inefficient fatty acid oxidation

23. Bayesian Classifiers with Consensus Gene Selection: A Case Study in the Systemic Lupus Erythematosus

26. E2F1 and E2F2-mediated repression of CPT2 establishes a lipid-rich tumor-promoting environment

29. E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment

31. WED-408 - E2F2-promoted DNA damage in NASH worsens the metabolic scenario

32. WED-404 - The E2F2-miR34a-5p axis is involved in the biliary metabolism dysregulation in NASH

33. SAT-215 - Targeting the E2F/MCM axis in cholangiocarcinoma halts disease progression in experimental models by rewiring lipid metabolism

34. FRI-395 - E2F2 deficiency protects from acetaminophen-induced hepatotoxicity while E2F1 is required to prevent the devastating effects

37. Neurogenin promotes neurogenesis and inhibits glial differentiation by independent mechanisms

41. E2F-1 functions in mice to promote apoptosis and suppress proliferation

43. Does arterial hypertension influence the onset of Huntington’s disease?

45. PS-008-E2F2 mediated repression of fatty acid B-oxidation is mitigated through CREB1 in progressive non-alcoholic fatty liver disease

50. Exploring Genetic Factors Involved in Huntington Disease Age of Onset: E2F2 as a New Potential Modifier Gene

Catalog

Books, media, physical & digital resources